Novel 2-Thiazolylhydrazone with Druggable Properties for Antifungal Application

Overview

Journal J Fungi (Basel)

Date 2025 Jan 24

PMID 39852488

Authors

Wallace Cordeiro de Morais

Gustavo Henrique Oliveira Costa

Vinicius Leal Pitcella

Joao Victor Vanolli Protti

Carolina Paula de Souza Moreira

Jose Eduardo Goncalves

Susana Johann

Renata Barbosa de Oliveira

Affiliations

Soon will be listed here.

Abstract

Fungal infections have become a growing concern in healthcare, particularly in immunocompromised individuals, with species like , , and posing significant challenges due to rising resistance and limited treatment options. In response, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve its water solubility and pharmacokinetic properties. The compound demonstrated a broad antifungal spectrum, particularly effective against and , with minimal irritant potential and low cytotoxicity. RW3 showed favorable solubility and high intestinal permeability, indicating potential for oral administration. The results suggest RW3 as a promising lead for further development as a therapeutic agent for systemic fungal infections. These findings underscore the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.

References

Yee S . In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man--fact or myth. Pharm Res. 1997; 14(6):763-6. DOI: 10.1023/a:1012102522787. View

Kontoyiannis D . Antifungal Resistance: An Emerging Reality and A Global Challenge. J Infect Dis. 2017; 216(suppl_3):S431-S435. DOI: 10.1093/infdis/jix179. View

Bender C, Partecke L, Kindel E, Doring F, Lademann J, Heidecke C . The modified HET-CAM as a model for the assessment of the inflammatory response to tissue tolerable plasma. Toxicol In Vitro. 2010; 25(2):530-7. DOI: 10.1016/j.tiv.2010.11.012. View

Amidon G, Lennernas H, Shah V, Crison J . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12(3):413-20. DOI: 10.1023/a:1016212804288. View

Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View

Oliveira N, Dos Santos Junior V, Pierotte I, Leocadio V, Santana L, Marques G . Discovery of Lead 2-Thiazolylhydrazones with Broad-Spectrum and Potent Antifungal Activity. J Med Chem. 2023; 66(24):16628-16645. DOI: 10.1021/acs.jmedchem.3c01105. View

Glomme A, Marz J, Dressman J . Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J Pharm Sci. 2005; 94(1):1-16. DOI: 10.1002/jps.20212. View

Wang Y, Chen X . QSPR model for Caco-2 cell permeability prediction using a combination of HQPSO and dual-RBF neural network. RSC Adv. 2022; 10(70):42938-42952. PMC: 9058322. DOI: 10.1039/d0ra08209k. View

Firacative C, Trilles L, Meyer W . Recent Advances in and Cryptococcosis. Microorganisms. 2022; 10(1). PMC: 8779235. DOI: 10.3390/microorganisms10010013. View

10.

Sanchotene K, Brandolt T, Baracy Klafke G, Poester V, Xavier M . In vitro susceptibility of Sporothrix brasiliensis: Comparison of yeast and mycelial phases. Med Mycol. 2017; 55(8):869-876. DOI: 10.1093/mmy/myw143. View

11.

Veseli A, Kristl A, Akelj S . Proof-of-concept for a miniaturized shake-flask biopharmaceutical solubility determination by sonic mixing. Pharmazie. 2020; 75(12):626-631. DOI: 10.1691/ph.2020.0063. View

12.

Orofino-Costa R, de Macedo P, Rodrigues A, Bernardes-Engemann A . Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics. An Bras Dermatol. 2017; 92(5):606-620. PMC: 5674690. DOI: 10.1590/abd1806-4841.2017279. View

13.

Jarc T, Novak M, Hevir N, Rizner T, Kreft M, Kristan K . Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines. J Pharm Pharmacol. 2019; 71(8):1231-1242. DOI: 10.1111/jphp.13111. View

14.

Sears D, Schwartz B . Candida auris: An emerging multidrug-resistant pathogen. Int J Infect Dis. 2017; 63:95-98. DOI: 10.1016/j.ijid.2017.08.017. View

15.

de Oliveira Santos G, Vasconcelos C, Lopes A, de Sousa Cartagenes M, Filho A, do Nascimento F . Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents. Front Microbiol. 2018; 9:1351. PMC: 6038711. DOI: 10.3389/fmicb.2018.01351. View

16.

Thambugala K, Daranagama D, Tennakoon D, Jayatunga D, Hongsanan S, Xie N . Humans vs. Fungi: An Overview of Fungal Pathogens against Humans. Pathogens. 2024; 13(5). PMC: 11124197. DOI: 10.3390/pathogens13050426. View

17.

de Araujo Lowndes Viera L, Silva R, da Silva C, Presgrave O, Boas M . Comparison of the different protocols of the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) by evaluating the eye irritation potential of surfactants. Toxicol In Vitro. 2021; 78:105255. DOI: 10.1016/j.tiv.2021.105255. View

18.

Kus M, Ibragimow I, Piotrowska-Kempisty H . Caco-2 Cell Line Standardization with Pharmaceutical Requirements and In Vitro Model Suitability for Permeability Assays. Pharmaceutics. 2023; 15(11). PMC: 10674574. DOI: 10.3390/pharmaceutics15112523. View

19.

Maziarz E, Perfect J . Cryptococcosis. Infect Dis Clin North Am. 2016; 30(1):179-206. PMC: 5808417. DOI: 10.1016/j.idc.2015.10.006. View

20.

Ozturk A, Cevikelli T, Tilki E, Guven U, Kiyan H . Ketorolac Tromethamine Loaded Nano-Spray Dried Nanoparticles: Preparation, Characterization, Cell Viability, COL1A1 Gene Simulation and Determination of Anti-inflammatory Activity by HET-CAM Assay. Curr Drug Deliv. 2023; 20(6):830-840. DOI: 10.2174/1567201820666230125144133. View